The preclinical biopharmaceutical firm develops nucleic acid therapeutics that are stereopure, meaning their they are comprised of molecules with atoms uniformly arranged in three dimensions. According to the company, this enables the drugs to have more consistent pharmacologic properties. Its most advanced programs are in Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. All are pre-IND.
2015 Financials (6 mo.)($M): Operating Expenses: 7.2 (+220.6%); Net Loss: (7.2) (-238.5%): Cash Burn: (3.0) (-50.6%).
Subscribe for full text news in your inbox